


**Product Name** : EAPB02303  
**Cat. No.** : PC-20673  
**CAS No.** : 1958290-51-1  
**Molecular Formula** : C<sub>17</sub>H<sub>14</sub>N<sub>4</sub>O<sub>2</sub>  
**Molecular Weight** : 306.33  
**Target** : Microtubule/Tubulin  
**Solubility** : 10 mM in DMSO



CAS: 1958290-51-1

## Biological Activity

EAPB02303 (EAPB 02303) is a novel **microtubule**-disrupting agent with in-vivo activity in PDAC and in-vitro synergy with Paclitaxel, inhibits A375 melanoma cell line with IC<sub>50</sub> of 3 nM.

EAPB02303 does not inhibit tubulin polymerization.

EAPB02303 exerts activity at low nanomolar concentrations in-vitro in PDAC cell lines and 3D models, and is able to reduce tumor growth in our xenografts in-vivo mouse models.

EAPB02303 is a potent synergy with Paclitaxel at lower concentrations of both compounds.

EAPB02303 induces mitosis arrest and impairment of spindle assembly.

EAPB02303 treatment reduced tumor size and weight of the A375 human melanoma xenografts in a dose-dependent manner, correlated with a low mitotic index but not with necrosis.

## References

Patinote C, et al. *Eur J Med Chem.* 2021 Feb 15;212:113031.

Deleuze-Masqueufa C. et al. WO 2009 043934A1.

Kevin Bigot, et al. *Cancer Res* (2023) 83 (7\_Supplement): 5729.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com